US EditionScientists successfully achieve 'permanent disappearance of pancreatic cancer' in new study for cure
The triple combination therapy permanently removed pancreatic tumors in mice without major side effects, offering hope for future clinical trials according to Spanish researchers.
- On Jan. 30, 2026, researchers at the Spanish National Cancer Research Centre reported a triple therapy that permanently eliminated pancreatic tumors in mice, as published in the Proceedings of the National Academy of Sciences in December 2025.
- Facing late diagnosis and drug resistance, researchers tested triple combination therapy to overcome single-drug therapies' failure in pancreatic ductal adenocarcinoma with low survival rate.
- In lab tests, the triple combination therapy shrank genetically engineered mouse tumors and patient-derived tumor xenografts with no major side effects and was well tolerated in mice.
- Authors said `the path to clinical use will be difficult and `a ways off`, according to NDTV, because results are only in mice.
- Lead researcher Dr. Mariano Barbacid, who earned a PhD at Universidad Complutense, faced online comments about a port-wine birthmark, prompting social media defenders to stress the potential breakthrough.
24 Articles
24 Articles
Through tritherapy, scientists at the Madrid Cancer Research Centre have succeeded in eradicating pancreatic tumours in this rodent, without any resistance appearing.
It is, without any doubt, the scientific advance of the year – despite meeting at the beginning of 2026 – and one of the most important of the century.
The scientific team of Mariano Barbacid, biochemist of the National Center for Oncological Research (CNIO) in Spain, managed to eliminate in mice the most common pancreatic cancer: ductal adenocarcinoma. The researchers developed a combination therapy of three drugs that prevents the appearance of resistances, as normally happens with chemotherapy, and that has no important side effects. This would be the first therapy to achieve complete healin…
Coverage Details
Bias Distribution
- 57% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
